CAJ | 학술논문

目的：观察多西他赛联合奈达铂化疗同步调强适形放疗治疗局部晚期鼻咽癌的协同作用。方法：回顾性分析72例同步放化疗的局部晚期鼻咽癌患者，均为芋~郁期，随机分为2组，同步组：多西他赛联合奈达铂化疗同步调强适形放疗42例；单纯组：单纯调强放疗30例。结果：同步组和单纯组多所有患者鼻咽肿瘤和颈部转移淋巴结均完全缓解，同步组所有病例均无局部区域进展，1、2年总生存率分别为96.4%、92.9%；单纯组总生存率分别为95.0%、75.0%。两组间2年局部区域无进展生存率、无远处转移生存率差异有统计学意义（P<0.05），总生存率差异无统计学意义（P>0.05）；血液学毒性和胃肠道反应差异有统计学意义（P<0.05）。结论：多西他赛联合奈达铂化疗同步调强适形放疗治疗局部晚期鼻咽癌疗效较好，不良反应可以耐受。
목적：관찰다서타새연합내체박화료동보조강괄형방료치료국부만기비인암적협동작용。방법：회고성분석72례동보방화료적국부만기비인암환자，균위우~욱기，수궤분위2조，동보조：다서타새연합내체박화료동보조강괄형방료42례；단순조：단순조강방료30례。결과：동보조화단순조다소유환자비인종류화경부전이림파결균완전완해，동보조소유병례균무국부구역진전，1、2년총생존솔분별위96.4%、92.9%；단순조총생존솔분별위95.0%、75.0%。량조간2년국부구역무진전생존솔、무원처전이생존솔차이유통계학의의（P<0.05），총생존솔차이무통계학의의（P>0.05）；혈액학독성화위장도반응차이유통계학의의（P<0.05）。결론：다서타새연합내체박화료동보조강괄형방료치료국부만기비인암료효교호，불량반응가이내수。
Objective:observation on docetaxel combined cisplatin chemotherapy concurrent intensity-modulated radiotherapy in treatment of local advanced nasopharyngeal carcinoma in synergy.Methods: a retrospective analysis of 72 cases of concurrent chemoradio therapy for locally advanced nasopharyngeal carcinoma ⅲ-ⅳ stage, were randomly divided into 2 groups, a syn-chronization group: docetaxel combined cisplatin chemotherapy intensity-modulated radiotherapy in 42 cases; Simple groups:simple intensity modulated radiotherapy for 30 patients.Results:the synchronized group and the group all complete remission in patients with nasopharyngeal cancer and metastatic lymph nodes of the neck are, in all cases without local regional progress for a synchronization group, 1-and 2-year overall survival rate was 96.4%, 92.9%; Simple overall survival rates were 95% and 75%.Two groups of 2-year locoregional progression-free survival, distant metastasis-free survival differences were statistically significant (P<0.05) , no statistically significant difference in overall survival (P>0.05) ;Hematologic toxicity and gastrointesti-nal reaction and the difference was statistically significant (P<0.05) .Conclusion: docetaxel combined cisplatin chemotherapy concurrent intensity-modulated radiotherapy in treatment of local advanced nasopharyngeal carcinoma curative effect adverse re-action can be tolerated.